PURPOSE Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with current standard-of-care therapies. Homologous recombination repair (HRR) gene alterations, including BRCA1/2 alterations, can sensitize cancer cells to poly (ADP-ribose) polymerase inhibition, which may improve outcomes in treatment-naïve mCRPC when combined with androgen receptor signaling inhibition. METHODS MAGNITUDE (ClinicalTrials.gov identifier: NCT03748641 ) is a phase III, randomized, double-blinded study that evaluates niraparib and abiraterone acetate plus prednisone (niraparib + AAP) in patients with (HRR+, n = 423) or without (HRR−, n = 247) HRR-associated gene alterations, as prospectively determined by tissue/plasma-based assays. Patients were assigned 1:1 to receive niraparib + AAP or placebo + AAP. The primary end point, radiographic progression-free survival (rPFS) assessed by central review, was evaluated first in the BRCA1/2 subgroup and then in the full HRR+ cohort, with secondary end points analyzed for the full HRR+ cohort if rPFS was statistically significant. A futility analysis was preplanned in the HRR− cohort. RESULTS Median rPFS in the BRCA1/2 subgroup was significantly longer in the niraparib + AAP group compared with the placebo + AAP group (16.6 v 10.9 months; hazard ratio [HR], 0.53; 95% CI, 0.36 to 0.79; P = .001). In the overall HRR+ cohort, rPFS was significantly longer in the niraparib + AAP group compared with the placebo + AAP group (16.5 v 13.7 months; HR, 0.73; 95% CI, 0.56 to 0.96; P = .022). These findings were supported by improvement in the secondary end points of time to symptomatic progression and time to initiation of cytotoxic chemotherapy. In the HRR− cohort, futility was declared per the prespecified criteria. Treatment with niraparib + AAP was tolerable, with anemia and hypertension as the most reported grade ≥ 3 adverse events. CONCLUSION Combination treatment with niraparib + AAP significantly lengthened rPFS in patients with HRR+ mCRPC compared with standard-of-care AAP.

A Ad dd dr re es ss s f fo or r c co or rr re es sp po on nd de en nc ce e: : Konrad Tałasiewicz MD, Students' Scientific Group at Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, 7 Debinki St, Poland, phone: +48 888 037 728, , 401 females, 493 males attending high schools (n = 481) or technical colleges (n = 419). The study was based on a direct anonymous questionnaire that consisted of fourteen multiple choice questions. R Re es su ul lt ts s: : On average, 50.3% of questions were answered correctly. 57.8% of participants stated that they had suffered from acne. As regards the causes, more than half (59.5%) of participants stated that acne is connected to eating and hygiene habits. 40.5% of students considered acne infectious. The study revealed that many "false beliefs" exist. 26.4% of adolescents believe that starting sexual activity can influence healing. Considering the effectiveness of curing acne in adolescence, 24.2% of participants do not see a point in early treatment. Regarding the sources of knowledge about acne, most adolescents use the internet, teenage newspapers and friends' opinions. Only 41.2% want to learn more, and almost 90% consider their knowledge sufficient. C Co on nc cl lu us si io on ns s: : The results from a large population-based study indicate that the knowledge about acne is insufficient, which reveals the need for introducing educational programs in schools.K Ke ey y w wo or rd ds s: : acne vulgaris, knowledge, treatment.

No abstract

Oncological treatment is often associated with a wide range of adverse effects. The article focuses on systemic complications that may occur during the hormonal therapy of prostate and breast cancer. Considering that current treatments are increasingly effective, the number of patients suffering from early and remote complications of cancer therapy can be expected to rise. Many undergo radical treatment and in this group in particular, close attention should be paid to the prevention, early diagnosis, and treatment of adverse effects. Hormonal disorders and their complications considerably affect the quality of life and life expectancy by upsetting general systemic homeostasis. NOWOTWORY J Oncol 2017; 67, 3: 206-214

No abstract